This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.
“Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito
At a meeting of the board of trustees on May 16, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) elected Haruo Naito, president of Eisai, as chairman upon the ... ＞ Read full story- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting (May.18)
- “Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda (May.18)
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology (May.18)
- Ishibashi to Become SSP President, Torii to Be Withdrawn from Presidency (May.18)
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System (May.18)
| Final Costs to Be Confirmed by Product, Changing from Manufacturer Basis: Medipal Group (May.16) | Santen to Establish Presence in Market for Back-of-the-Eye Area with VEGF Trap-Eye (May.16) | Midterm Plan to Overcome Generic Versions of Actos, Setting Sights on Emerging Markets: Takeda (May.15) |
| Astellas to File for MDV3100 by June in Europe and US (May.15) | DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America (May.14) | Greater Concern than Hope about HTA: Mr Zulueta of PhRMA (May.14) |
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System(May.18)
- DPJ Subcommittee Proposes Inclusion of 3 Subsidized Vaccines in Regular Vaccination Programs(May.16)
- Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents(May.14)
- “Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda(May.18)
- Ono to Conduct Joint Research with German Pharmaceutical Company Using Affilin Technology(May.18)
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting(May.18)
-
“Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito(May.18)
-
Greater Concern than Hope about HTA: Mr Zulueta of PhRMA(May.14)
- Serious ADR for Abatacept shows 2.4%, Lower Than Other RA Drugs: All-Case PMS Interim Analysis(May.07)
-
St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions(Apr.27)
- Remission Rate Equal in Antirheumatic Drugs, Anti-TNF Drugs in JaSTAR’s Interim Analysis(Apr.26)
- Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
- Law-evading drug：
脱法ドラッグ - Legal drug：
合法ドラッグ - Illegal drug：
違法ドラッグ
- Social Networking in Japan’s Pharmaceutical Industry
- Morishita Jintan, AnGes MG Jointly Research and Develop Oral Vaccine(May.18)
- Pfizer Resubmit NDA for Fesoterodine Fumarate in March(May.18)
- Eisai Sets Domestic Sales Forecast for Aricept at 90 Billion Yen on Impact of Generics(May.17)
- Double-Digit Drop in Sales, Profits Reported Due to Patent Expiration of Aricept: Eisai(May.17)
- Nichi-Iko, sanofi-aventis to Copromote Lipitor Generic Aiming at Cumulative Sales of 10 Billion Yen over 5 Years(May.17)
- 1.
- Struggles in US...
- 2.
- Greater Concern...
- 3.
- “Figures to Loo...
- 4.
- The Growing Pre...
- 5.
- Astellas to Fil...
- 1.
- Astellas Collab...
- 2.
- 90% of Pharmaci...
- 3.
- DSP Completes A...
- 4.
- JPMA Opposes Ha...
- 5.
- Kaketsuken and ...